Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC
: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. (616 KB)
The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics Toxicities and outcomes of 616 ibrutinib-treated patients in
The study highlighted a few differences between "real-world" patients and those in trials: (616 KB)
: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can: